One-quarter of patients with axial SpA remain flare-free after ceasing etanercept

In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology.
“Patients with [axial SpA (axSpA)] typically have disease onset early in life, and are likely to start [TNF inhibitor (TNFi)] treatment early; therefore, treatment withdrawal upon achieving inactive disease is especially relevant,” Filip Van den Bosch, MD, PhD, of the department of internal medicine and pediatrics at Ghent University, in Belgium,

In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology.
“Patients with [axial SpA (axSpA)] typically have disease onset early in life, and are likely to start [TNF inhibitor (TNFi)] treatment early; therefore, treatment withdrawal upon achieving inactive disease is especially relevant,” Filip Van den Bosch, MD, PhD, of the department of internal medicine and pediatrics at Ghent University, in Belgium,